SEC Form 4 · accession 0001104659-15-003029
Radius Health, Inc. · RDUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owners
Katherine Priestley
10% Owner
F2 Capital Ltd
10% Owner
F2 Bioscience IV L.P.
10% Owner
F2 Bioscience IV GP Ltd.
10% Owner
F2 Bio Ventures V L.P.
10% Owner
F2 Bio Ventures GP Ltd.
10% Owner
Globeways Holdings Ltd
10% Owner
Period of report
Jan 16, 2015
Accepted (ET)
Jan 16, 2015 · 9:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001428522
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 16, 2015 | J | 1,794,983 | — | D | 0 | D | |
| Common StockF3,F4 | Jan 16, 2015 | J | 871,851 | — | D | 0 | I | By Fund |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock WarrantF1,F2 | $2.694 | Jan 16, 2015 | J | 249,932 | D | Feb 14, 2014 | Feb 14, 2019 | Common Stock | 249,932 | 0 | D |
| Common Stock WarrantF3,F4 | $2.694 | Jan 16, 2015 | J | 121,396 | D | Feb 14, 2014 | Feb 14, 2019 | Common Stock | 121,396 | 0 | I |
Explanation of responses
- F1Reflects a liquidating pro rata distribution by F2 Bioscience IV L.P. ("F2 IV") to its limited and general partners.
- F2The reported securities are owned directly by F2 IV. F2 Bioscience IV GP Ltd. ("F2 IV GP") is the General Partner of F2 IV. Katherine Priestley and Globeways Holdings Limited ("Globeways") are members of F2 IV GP. F2 Capital Limited ("F2 Capital") is an investment adviser to F2 IV. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- F3Reflects a liquidating pro rata distribution by F2 Bio Ventures V L.P. ("F2 Bio") to its limited and general partners.
- F4The reported securities are owned directly by F2 Bio. F2 Bio Ventures GP Ltd. is the General Partner of F2 Bio. Globeways is the sole member of F2 Bio Ventures GP Ltd. F2 Capital is an investment adviser to F2 Bio. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.